Breaking News
Quotes
All Instrument Types
  • All Instrument Types
  • Indices
  • Equities
  • ETFs
  • Funds
  • Commodities
  • Currencies
  • Crypto
  • Bonds
  • Certificates

Please try another search

Search website for: 
Popular News
More
Popular Analysis
More
More
/Free Sign Up
 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details
Close

Editas Medicine Inc (EDIT)

Create Alert
Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Editas Medicine's earnings

Delivery Method

Status

Create Manage my alerts 
Back
Add to/Remove from a Portfolio Add to Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
 
Create a new watchlist Create
Create a new holdings portfolio Add Create
+ Add another position Close
40.84 -2.17    -5.05%
23/07 - Closed. Currency in USD ( Disclaimer )
Type:  Equity
Market:  United States
ISIN:  US28106W1036 
CUSIP:  28106W103
  • Volume: 1,021,329
  • Bid/Ask: 40.45 / 41.50
  • Day's Range: 40.18 - 42.63
Editas Medicine 40.84 -2.17 -5.05%

EDIT Earnings

 
The latest earnings per stock, revenues and financial reports for Editas Medicine (EDIT).
Latest Release

May 05, 2021

EPS / Forecast

-0.86 / -0.7438

Revenue / Forecast

6.5M / 5.83M

Revenue
EPS
 Forecast
 
Release Date Period End EPS /  Forecast Revenue /  Forecast
Nov 10, 2021 09/2021 -- /  -0.8622 -- /  6.03M
Aug 10, 2021 06/2021 -- /  -0.8235 -- /  6.03M
May 05, 2021 03/2021 -0.86 /  -0.7438 6.5M /  5.83M
Feb 25, 2021 12/2020 -1 /  -0.76 11.42M /  5.64M
Nov 05, 2020 09/2020 0.12 /  -0.626 62.84M /  6.36M
Aug 06, 2020 06/2020 -0.43 /  -0.79 10.75M /  6.34M
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

I Agree

EDIT Comments

Write your thoughts about Editas Medicine Inc
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Repo Man
Repo Man Jun 30, 2021 4:53PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Lift off🚀
Reply
2 0
Report
Louis Lee
Louis Lee Feb 23, 2021 6:45PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Lost half from the peak
Reply
1 0
Report
David Noy
David Noy Feb 19, 2021 10:39AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
stock is good long term
Reply
5 0
Report
יהונתן כהן
יהונתן כהן Feb 15, 2021 9:08AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Buy
Reply
2 0
Report
David Noy
David Noy Feb 15, 2021 9:08AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Yes
Reply
0 0
Report
Bastian Mutschelknaus
Bastian Mutschelknaus Feb 12, 2021 5:09AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
buy
Reply
1 0
Report
Silvius Iancu
Silvius Iancu Feb 10, 2021 11:34AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Buy
Reply
3 0
Report
stephen nadeau
stephen nadeau Jan 29, 2021 8:12AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
buy
Reply
5 1
Report
stephen nadeau
stephen nadeau Jan 29, 2021 8:11AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
buy
Reply
2 1
Report
oliver yell
oliver yell Jan 28, 2021 11:39AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
what happening with this stock... stay or leave?
Reply
0 0
Report
Diego Martins
Diego Martins Jan 21, 2021 1:26PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
editas has announced the pricing of an underwritten offering of 3,500,000 shares of its common stock at a public offering price of $66.00 per share. normal to fall when it happens and can be an opportunity to enter in the deep.
Reply
2 0
Report
Nai Fotu
Nai Fotu Jan 21, 2021 1:26PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
NICE!!!  i've been waiting for a good chance to get back into this stock.
Reply
0 0
Report
Mister Bert
Mister Bert Jan 21, 2021 1:26PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Nai Fotu  Whats the price point that you will buy? Monday will be the close for the offering at $66 which is $2 above what it is now, but there will be 3million more shares now. Will the market price increase because of that or will it continue down?
Reply
0 0
Report
Nai Fotu
Nai Fotu Jan 21, 2021 1:26PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Mister Bert  Getting back into this company was my goal at any rate. being that is dropped down to 63.78, that was perfect for me. this stock will continue to climb up long term.
Reply
0 1
Report
Mister Bert
Mister Bert Jan 21, 2021 1:26PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Nai Fotu  Well its Monday and it hit that price again today a few times. Support is at $61 and it hit that at 8:05am today (but the entire market suspiciously dipped exactly at that point too). I dont know what to do with this. I wish the best of luck to you.
Reply
0 0
Report
Diego Martins
Diego Martins Jan 21, 2021 1:26PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
editas has announced the pricing of an underwritten offering of 3,500,000 shares of its common stock at a public offering price of $66.00 per share. normal to fall when it happens and can be an opportunity to enter in the deep.
Reply
1 0
Report
Nijat Rzayev
Nijat Rzayev Jan 19, 2021 11:37AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Ark invest selling that is why I think.
Reply
0 0
Report
Richard Lusk
Richard Lusk Jan 19, 2021 11:37AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
No. I checked
Reply
0 0
Report
David Noy
David Noy Jan 19, 2021 11:01AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Why down
Reply
0 0
Report
Richard Lusk
Richard Lusk Jan 19, 2021 11:01AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
JP Morgan put a sell recommendation on the company
Reply
0 0
Report
Kevin Durant
Kevin Durant Jan 11, 2021 10:07AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Some news came out?
Reply
1 0
Report
Mister Bert
Mister Bert Jan 11, 2021 10:07AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
They got FDA approval to test  a Sickel Cell Anemia treatment. Gen X old timers and Millenials used to consider that a buy. The new Gen Z traders that are flooding the stock market only like investing in dream markets. FDA approval for Gen Z investors and traders means the dream market is coming to an end and the real market is here, so they pull out.
Reply
0 0
Report
Luna Ley
Luna Ley Jan 02, 2021 12:15PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Buy this dip.
Reply
5 0
Report
Adam Anderson
Adam Anderson Dec 21, 2020 2:43PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Its clear companies like this crispr etc....is where the trillion dollar valuation need to go. anything that has the potential to extend life should always have more value them a phone or social media app or a retailer that sells everything online....this is a no brainer. if demographics aren't going then life extension is the only growth
Reply
9 1
Report
Nich Schmidt
Nich Schmidt Dec 21, 2020 12:11PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Been watching this run up all morning.  I recently opened a long term hold position at 66.52, but the trends were too juicy so I scalped a few of the swings, but nonetheless up almost 50% as of open today jesus.
Reply
5 1
Report
Repo Man
Repo Man Dec 21, 2020 12:11PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Well done, long term holder here, very happy!
Reply
0 0
Report
Nai Fotu
Nai Fotu Dec 15, 2020 11:27AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
This is a great stock to get into I believe.
Reply
3 0
Report
Stephen Boyle
Stephen Boyle Dec 15, 2020 11:27AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
boy were you ever right!!!!!
Reply
0 0
Report
William Kelly
William Kelly Dec 11, 2020 5:32PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
Not alot of comments on this company. Surprised after seeing it shoot up nearly $30 overnight.  Any details on the renewed interest?
Reply
0 0
Report
Joo Lee
Joo Lee Oct 07, 2020 1:45PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
This company has a patent for the CRISPR/Cas9-related technique.
Reply
0 0
Report
Joo Lee
Joo Lee Oct 07, 2020 9:51AM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
A novel laureate!
Reply
0 0
Report
Repo Man
Repo Man Apr 20, 2020 1:55PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
This is a 50 bagger given time and that they aren't bought out before. World changing medicine and they hold the US patents.
Reply
6 2
Report
André Reis
André Reis Jan 09, 2018 5:09PM ET
Save
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Block User
A study which was NOT peer-reviewed? This is all misplaced fear, EDITAS is the future of medicine due to patents of the technology. BULLISH!
Reply
6 3
Report
 
Are you sure you want to delete this chart?
Delete Cancel
 
Post
 
Replace the attached chart with a new chart ?
Replace Cancel
1000
Comment Guidelines
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Cancel Attach
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Confirm Block Cancel
Ok
Report this comment

I feel that this comment is:

Submit
Comment flagged

Thank You!

Your report has been sent to our moderators for review
Close
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email